250,000 Kenyans screened for diabetes, hypertension in Boehringer programme
Boehringer Ingelheim says it has screened more than 250,000 Kenyans and placed over 20,000 on treatment for diabetes and hypertension since 2022 through its Access to Healthcare programme targeting un
